<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vedomostiregmed</journal-id><journal-title-group><journal-title xml:lang="ru">Регуляторные исследования и экспертиза лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Regulatory Research and Medicine Evaluation</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3034-3062</issn><issn pub-type="epub">3034-3453</issn><publisher><publisher-name>Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.30895/1991-2919-2025-15-5-583-594</article-id><article-id custom-type="elpub" pub-id-type="custom">vedomostiregmed-793</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КОНТРОЛЬ КАЧЕСТВА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>QUALITY CONTROL</subject></subj-group></article-categories><title-group><article-title>Контроль стерильности высокотехнологичных лекарственных препаратов: влияние питательной среды, времени анализа и количества образца</article-title><trans-title-group xml:lang="en"><trans-title>Sterility Control of Advanced Therapy Medicinal Products: Impact of Growth Medium, Analysis Time, and Sample Quantity</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5966-5822</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рощина</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Roshchina</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рощина Марина Владимировна, канд. фарм. наук </p><p>Петровский б-р, д. 8, стр. 2, Москва, 127051</p></bio><bio xml:lang="en"><p>Marina V. Roshchina, Cand. Sci. (Pharm.) </p><p>8/2 Petrovsky Blvd, Moscow 127051</p></bio><email xlink:type="simple">roshchina@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1773-7423</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сахно</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Sakhno</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сахно Надежда Геннадьевна, канд. фарм. наук </p><p>Петровский б-р, д. 8, стр. 2, Москва, 127051</p></bio><bio xml:lang="en"><p>Nadezhda G. Sakhno, Cand. Sci. (Pharm.) </p><p>8/2 Petrovsky Blvd, Moscow 127051</p></bio><email xlink:type="simple">sakhno@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4825-8356</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гунар</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gunar</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гунар Ольга Викторовна, д-р фарм. наук </p><p>Петровский б-р, д. 8, стр. 2, Москва, 127051</p></bio><bio xml:lang="en"><p>Olga V. Gunar, Dr. Sci. (Pharm.) </p><p>8/2 Petrovsky Blvd, Moscow 127051</p></bio><email xlink:type="simple">Gunar@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Centre for Expert Evaluation of Medicinal Products</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>06</day><month>11</month><year>2025</year></pub-date><volume>15</volume><issue>5</issue><fpage>583</fpage><lpage>594</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Рощина М.В., Сахно Н.Г., Гунар О.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Рощина М.В., Сахно Н.Г., Гунар О.В.</copyright-holder><copyright-holder xml:lang="en">Roshchina M.V., Sakhno N.G., Gunar O.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.vedomostincesmp.ru/jour/article/view/793">https://www.vedomostincesmp.ru/jour/article/view/793</self-uri><abstract><sec><title>ВВЕДЕНИЕ</title><p>ВВЕДЕНИЕ. Контроль стерильности высокотехнологичных лекарственных препаратов (ВТЛП) осложнен рядом факторов, в том числе: ограничением объема доступной пробы, чувствительностью препаратов к условиям тестирования, ограничением срока хранения препаратов. Контроль классическими фармакопейными методами зачастую не позволяет своевременно и достоверно подтвердить стерильность ВТЛП, что снижает доступность препаратов для пациентов и возможность быстрого проведения необходимой терапии. Повысить скорость и эффективность проведения контроля стерильности можно путем разработки альтернативных ускоренных микробиологических методик, учитывающих специфику ВТЛП.</p></sec><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ. Оптимизация методики контроля стерильности высокотехнологичных лекарственных препаратов методом колориметрического определения углекислого газа.</p></sec><sec><title>МАТЕРИАЛЫ И МЕТОДЫ</title><p>МАТЕРИАЛЫ И МЕТОДЫ. Объект исследования — образец высокотехнологичного лекарственного генотерапевтического препарата. Используемые тест-штаммы: Bacillus subtilis ATCC 6633, Pseudomonas aeruginosa ATСС 9027, Staphylococcus aureus ATCC 6538, Clostridium sporogenes ATCC 19404, Cutibacterium acnes (Propionibacterium acnes) NCTC 737, Candida albicans АТСС 10231, Aspergillus brasiliensis АТСС 16404, Aspergillus fumigatus ВКПМ F-62, Aspergillus terreus ВКПМ F-1269, Penicillium chrysogenum ВКПМ F-3. Питательные среды: SA, SN и iLYM для прибора BacT/ALERT 3D Dual T — флаконы с модифицированными средами на основе триптиказо-соевого бульона; триптиказо-соевый бульон (TSB) и жидкая тиогликолевая среда (FTM) — пробирки с фармакопейными питательными средами, предусмотренными для проведения испытания по показателю «Стерильность» методом прямого посева. Оборудование: ламинарный шкаф Purifier Logic A2, система BacT/ALERT 3D Dual T с автоматическим мониторингом и детекцией контаминированных флаконов и построением кривых роста микроорганизмов. Контаминированные образцы ВТЛП готовили с теоретической концентрацией тест-штаммов 3 КОЕ/мл. Посев осуществляли в объемах 0,1; 0,5 и 1,0 мл в двадцатикратной повторности в пробирки и флаконы с соответствующими питательными средами. Использовали как фармакопейные среды (TSB, FTM), так и модифицированные, предназначенные для системы BacT/ALERT (SA, SN, iLYM). Инкубацию при прямом посеве проводили в течение 14 сут; анализ в системе BacT/ALERT длился 7 сут при непрерывном автоматическом мониторинге при температурах 32,5±2,5 и 22,5±2,5 °С для бактерий и грибов соответственно. Результаты учитывали визуально (прямой посев) и по кривым роста содержания CO2 (альтернативный метод).</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. В ходе исследования установлено, что чувствительность BacT/ALERT 3D Dual T при анализе проб объемом 0,5 мл составила ≥80% для аэробных и анаэробных бактерий, а также ≥90% для дрожжевых и плесневых грибов при использовании модифицированной среды iLYM с предварительной аэрацией. В условиях прямого посева тот же уровень выявления требовал не менее 1,0 мл пробы. Сроки выявления контаминации с использованием BacT/ALERT были на 0,38–2,4 сут меньше, чем при фармакопейной методике прямого посева, при сохранении полноты обнаружения всех тест-штаммов, за исключением Candida albicans, время детектирования которого одинаково при использовании обеих методик. Частота получения ложноотрицательных результатов при выявлении плесневых грибов на среде SA достигала 13–70% в зависимости от штамма. Введение этапа кратковременной аэрации (5–7 с) при использовании среды iLYM снижало частоту ложноотрицательных результатов до 0–3%. Все тестируемые микроорганизмы, кроме Cutibacterium acnes, были полностью детектированы в течение ≤ 28 ч; для C. acnes время инкубации составило около 134 ч.</p></sec><sec><title>ВЫВОДЫ</title><p>ВЫВОДЫ. Альтернативный метод BacT/ALERT 3D Dual T превосходит традиционную фармакопейную методику по чувствительности, воспроизводимости и скорости анализа. Ложноотрицательные результаты при выявлении плесневых грибов на среде SA достигали 70%, но показана возможность их практически полного устранения при использовании аэрированной среды iLYM. Полный спектр тест-микроорганизмов достоверно выявляется за 7 сут обеими методиками, при этом время обнаружения контаминации с использованием альтернативной методики снижается на 0,38–2,4 сут. Объем пробы 0,5 мл в системе BacT/ALERT обеспечивает эффективное выявление контаминантов, что вдвое снижает расход ВТЛП по сравнению с фармакопейным методом (1,0 мл).</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>INTRODUCTION</title><p>INTRODUCTION. Sterility testing of advanced therapy medicinal products (ATMP) implies several challenges, including limited volume of available sample, product sensitivity to test conditions, and short shelf life. Classical pharmacopoeial test methods often fail to confirm sterility in a timely and reliable manner. The resulting drug availability for patients is reduced, as well as the opportunity for fast treatment with high-quality medicines. Faster alternative microbiological methods that reflect ATMP specificity of advanced therapy medicinal products can speed up and enhance sterility control.</p></sec><sec><title>AIM</title><p>AIM. This study aimed to optimise ATMP sterility control using colorimetric carbon dioxide detection.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS. We used an experimental sample of an ATMP as the test object. We challenged the system with the following test strains: Bacillus subtilis ATCC 6633, Pseudomonas aeruginosa ATCC 9027, Staphylococcus aureus ATCC 6538, Clostridium sporogenes ATCC 19404, Cutibacterium acnes (Propionibacterium acnes) NCTC 737, Candida albicans ATCC 10231, Aspergillus brasiliensis ATCC 16404, Aspergillus fumigatus VKPM F-62, Aspergillus terreus VKPM F-1269, Penicillium chrysogenum VKPM F-3. We used SA, SN, and iLYM bottles with pharmacopoeial growth media: modified tryptic soy broth for the BacT/ALERT 3D Dual T system, tryptic soy broth, and fluid thioglycollate medium in test tubes designed for sterility testing using direct inoculation. All manipulations took place in a Purifier Logic A2 laminar flow cabinet, with BacT/ALERT 3D Dual T system to automatically monitor cultures, detect contamination, and record microbial growth curves. We prepared artificially contaminated samples by adding 3 CFU/mL of each test strain. We inoculated 0.1, 0.5, and 1.0 mL sample volumes into appropriate media, performing 20 replicates for each condition. Growth media included both pharmacopoeial (tryptic soy broth, fluid thioglycollate) ones and modified media for BacT/ALERT (SA, SN, iLYM). We incubated the direct inoculation samples for 14 days. In the BacT/ALERT system, we ran a 7-day incubation with continuous monitoring at 32.5±2.5 °C for bacteria and 22.5±2.5 °C for fungi. We evaluated direct inoculation results visually and assessed BacT/ALERT results based on CO2 growth curves (alternative method).</p></sec><sec><title>RESULTS</title><p>RESULTS. The BacT/ALERT 3D Dual T system detected ≥80% of aerobic and anaerobic bacteria and ≥90 % of yeasts and molds at 0.5 mL sample volume using pre-aerated iLYM medium. In contrast, direct inoculation required 1.0 mL to reach similar detection levels. BacT/ALERT reduced the time to contamination detection by 0.38–2.4 days compared to direct inoculation, while identifying all test strains except Candida albicans that showed similar detectability in both methods. When using SA medium, false-negative results for molds made 13–70 % of cases, depending on the strain. Short-time iLYM aerating for 5–7 s before incubation reduced false negatives to 0–3 %. We successfully detected all tested microorganisms within 28 h, except for Cutibacterium acnes, which required up to 134 h.</p></sec><sec><title>CONCLUSIONS</title><p>CONCLUSIONS. The BacT/ALERT 3D Dual T system delivers higher sensitivity, reproducibility, and faster detection compared to traditional pharmacopoeial methods. False negative results for mold fungi in SA medium were as high as 70%. However, they can be significantly reduced using aerated iLYM medium. Both methods reliably detect all test organisms within 7 days, but alternative BacT/ALERT achieves detection 0.38–2.4 days sooner. Using a 0.5 mL sample volume with BacT/ALERT effectively detects contamination and reduces product use by half compared to pharmacopoeial testing (1.0 mL).</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>высокотехнологичные лекарственные препараты</kwd><kwd>контроль стерильности</kwd><kwd>альтернативные микробиологические методы</kwd><kwd>BacT/ALERT</kwd></kwd-group><kwd-group xml:lang="en"><kwd>advanced therapy medicinal products</kwd><kwd>ATMP</kwd><kwd>sterility testing</kwd><kwd>alternative microbiological methods</kwd><kwd>BacT/ALERT</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056-00001-25-00 на проведение прикладных научных исследований (номер государственного учета НИР 124022200093-9)</funding-statement><funding-statement xml:lang="en">The study reported in this publication was carried out as part of State Assignment No. 056-00001-25-00 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&amp;D Registry No. 124022200093-9).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Gonçalves E. Advanced therapy medicinal products: Value judgment and ethical evaluation in health technology assessment. Eur J Health Econ. 2019;21(3):311–20. https://doi.org/10.1007/s10198-019-01147-x</mixed-citation><mixed-citation xml:lang="en">Gonçalves E. Advanced therapy medicinal products: Value judgment and ethical evaluation in health technology assessment. Eur J Health Econ. 2019;21(3):311–20. https://doi.org/10.1007/s10198-019-01147-x</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Centers for Disease Control and Prevention. Multistate outbreak of fungal infection associated with injection of methylprednisolone acetate solution from a single compounding pharmacy. MMWR Morb Mortal Wkly Rep. 2012; 61(41):839–42. https://doi.org/10.15585/mmwr.mm6141a2</mixed-citation><mixed-citation xml:lang="en">Centers for Disease Control and Prevention. Multistate outbreak of fungal infection associated with injection of methylprednisolone acetate solution from a single compounding pharmacy. MMWR Morb Mortal Wkly Rep. 2012; 61(41):839–42. https://doi.org/10.15585/mmwr.mm6141a2</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bertoletti da Silva S, Rebello Lourenço F. Risk of false compliance/non compliance decisions for sterility test due to false negative and false positive test results. Chemometr Intell Lab Syst. 2020;200:104005. https://doi.org/10.1016/j.chemolab.2020.104005</mixed-citation><mixed-citation xml:lang="en">Bertoletti da Silva S, Rebello Lourenço F. Risk of false compliance/non compliance decisions for sterility test due to false negative and false positive test results. Chemometr Intell Lab Syst. 2020;200:104005. https://doi.org/10.1016/j.chemolab.2020.104005</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Deutschmann S, Paul M, Claassen-Willemse M, et al. Rapid sterility test systems in the pharmaceutical industry: Applying a structured approach to their evaluation, validation and global implementation. PDA J Pharm Sci Technol. 2023;77(3):211–35. https://doi.org/10.5731/pdajpst.2021.012672</mixed-citation><mixed-citation xml:lang="en">Deutschmann S, Paul M, Claassen-Willemse M, et al. Rapid sterility test systems in the pharmaceutical industry: Applying a structured approach to their evaluation, validation and global implementation. PDA J Pharm Sci Technol. 2023;77(3):211–35. https://doi.org/10.5731/pdajpst.2021.012672</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Thorpe TC, Wilson ML, Turner JE, et al. BacT/Alert: An automated colorimetric microbial detection system. J Clin Microbiol. 1990;28(7):1608–12. https://doi.org/10.1128/jcm.28.7.1608-1612.1990</mixed-citation><mixed-citation xml:lang="en">Thorpe TC, Wilson ML, Turner JE, et al. BacT/Alert: An automated colorimetric microbial detection system. J Clin Microbiol. 1990;28(7):1608–12. https://doi.org/10.1128/jcm.28.7.1608-1612.1990</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Goula A, Gkioka V, Michalopoulos E, et al. Advanced therapy medicinal products: challenges and perspectives in regenerative medicine. J Clin Med Res. 2020;12(12):780–6. https://doi.org/10.14740/jocmr3964</mixed-citation><mixed-citation xml:lang="en">Goula A, Gkioka V, Michalopoulos E, et al. Advanced therapy medicinal products: challenges and perspectives in regenerative medicine. J Clin Med Res. 2020;12(12):780–6. https://doi.org/10.14740/jocmr3964</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Рощина МВ, Сахно НГ, Гунар ОВ. Подходы к валидации альтернативной методики определения стерильности высокотехнологичных лекарственных препаратов. Химико фармацевтический журнал. 2025;59(2):58–64. https://doi.org/10.30906/0023-1134-2025-59-2-58-64.</mixed-citation><mixed-citation xml:lang="en">Roshchina MV, Sakhno NG, Gunar OV. Approaches to the validation of an alternative method for determining the sterility of high-tech medicines. Pharm Chem J. 2025;59(2):258– 63. https://doi.org/10.1007/s11094-025-03386-0</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Woods M, Lu H-Y, Benard F. Validation of the BacT/ALERT® 3D System for Sterility Testing of a 177 Lu-radiopharmaceutical. J Nucl Med. 2025;66(Suppl 1):25146.</mixed-citation><mixed-citation xml:lang="en">Woods M, Lu H-Y, Benard F. Validation of the BacT/ALERT® 3D System for Sterility Testing of a 177 Lu-radiopharmaceutical. J Nucl Med. 2025;66(Suppl 1):25146.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Jimenez L, Rana N, Amalraj J, et al. Validation of the BacT/ ALERT® 3D system for rapid sterility testing of biopharmaceutical samples. PDA J Pharm Sci Technol. 2012;66(1):38– 54. https://doi.org/10.5731/pdajpst.2012.00790</mixed-citation><mixed-citation xml:lang="en">Jimenez L, Rana N, Amalraj J, et al. Validation of the BacT/ ALERT® 3D system for rapid sterility testing of biopharmaceutical samples. PDA J Pharm Sci Technol. 2012;66(1):38– 54. https://doi.org/10.5731/pdajpst.2012.00790</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hussong D, Mello R. Alternative microbiology methods and pharmaceutical quality control. Am Pharm Rev. 2006;9(1):62–9.</mixed-citation><mixed-citation xml:lang="en">Hussong D, Mello R. Alternative microbiology methods and pharmaceutical quality control. Am Pharm Rev. 2006;9(1):62–9.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Rohner P, Pepey B, Auckenthaler R. Comparison of BacT/ ALERT with Signal blood culture system. J Clin Microbiol. 1995;33(2):313–7. https://doi.org/10.1128/jcm.33.2.313-317.1995</mixed-citation><mixed-citation xml:lang="en">Rohner P, Pepey B, Auckenthaler R. Comparison of BacT/ ALERT with Signal blood culture system. J Clin Microbiol. 1995;33(2):313–7. https://doi.org/10.1128/jcm.33.2.313-317.1995</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mastronardi C, Perkins H, Derksen P, et al. Evaluation of the BacT/ALERT 3D system for the implementation of in-house quality control sterility testing at Canadian Blood Services. Clin Chem Lab Med. 2010;48(8):1179–87. https://doi.org/10.1515/cclm.2010.240</mixed-citation><mixed-citation xml:lang="en">Mastronardi C, Perkins H, Derksen P, et al. Evaluation of the BacT/ALERT 3D system for the implementation of in-house quality control sterility testing at Canadian Blood Services. Clin Chem Lab Med. 2010;48(8):1179–87. https://doi.org/10.1515/cclm.2010.240</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Рощина МВ, Гунар ОВ, Сахно НГ. Применимость альтернативного метода для анализа стерильности лекарственных препаратов. Химико фармацевтический журнал. 2017;51(11):61–4. https://doi.org/10.30906/0023-1134-2017-51-11-61-64.</mixed-citation><mixed-citation xml:lang="en">Roshchina MV, Gunar OV, Sakhno NG. Applicability of an alternative method for sterility |testing of medicinal preparations. Pharm Chem J. 2018; 51(11):1045–8. https://doi.org/10.1007/s11094-018-1737-1</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Рощина МВ, Гунар ОВ, Сахно НГ. Методические особенности анализа стерильности биомедицинских клеточных продуктов. Биофармацевтический журнал. 2017;9(6):3–8. EDN: XHAWNY</mixed-citation><mixed-citation xml:lang="en">Roshchina MV, Gunar OV, Sakhno NG. Methodological features of sterility testing of biomedical cellular products. Biopharmaceutical Journal. 2017;9(6):3– 8 (In Russ.). EDN: XHAWNY</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Рощина МВ, Гунар ОВ, Сахно НГ. Предел обнаружения микроорганизмов при определении стерильности лекарственных средств. Химико-фармацевтический журнал. 2017;51(6):62–4. https://doi.org/10.30906/0023-1134-2017-51-6-62-64.</mixed-citation><mixed-citation xml:lang="en">Roshchina MV, Gunar OV, Sakhno NG. Limit of detection of microorganisms in drug sterility testing. Pharm Chem J. 2017;51(6):508–10. https://doi.org/10.1007/s11094-017-1644-x</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kvich L, Jensen PØ, Justesen US, et al. Incidence of Propionibacterium acnes in initially culture-negative thioglycollate broths: A prospective cohort study at a Danish university hospital. Clin Microbiol Infect. 2016;22(11):941–5. https://doi.org/10.1016/j.cmi.2016.07.036</mixed-citation><mixed-citation xml:lang="en">Kvich L, Jensen PØ, Justesen US, et al. Incidence of Propionibacterium acnes in initially culture-negative thioglycollate broths: A prospective cohort study at a Danish university hospital. Clin Microbiol Infect. 2016;22(11):941–5. https://doi.org/10.1016/j.cmi.2016.07.036</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kocoglu ME, Bayram A, Balci I. Evaluation of negative results of BacT/Alert 3D automated blood culture system. J Microbiol. 2005;43(3):257–9. PMID: 15995643</mixed-citation><mixed-citation xml:lang="en">Kocoglu ME, Bayram A, Balci I. Evaluation of negative results of BacT/Alert 3D automated blood culture system. J Microbiol. 2005;43(3):257–9. PMID: 15995643</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bugno A, Lira RS, Oliveira WA, et al. Application of the BacT/ALERT® 3D system for sterility testing of injectable products. Braz J Microbiol. 2015;46(3):743–7. https://doi.org/10.1590/S1517-838246320140587</mixed-citation><mixed-citation xml:lang="en">Bugno A, Lira RS, Oliveira WA, et al. Application of the BacT/ALERT® 3D system for sterility testing of injectable products. Braz J Microbiol. 2015;46(3):743–7. https://doi.org/10.1590/S1517-838246320140587</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hanna E, Rémuzat C, Auquier P, et al. Advanced therapy medicinal products: Current and future perspectives. J Mark Access Health Policy. 2016;4(1):31036. https://doi.org/10.3402/jmahp.v4.31036</mixed-citation><mixed-citation xml:lang="en">Hanna E, Rémuzat C, Auquier P, et al. Advanced therapy medicinal products: Current and future perspectives. J Mark Access Health Policy. 2016;4(1):31036. https://doi.org/10.3402/jmahp.v4.31036</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
